<div id="readability-page-1"><div><ul> <li>In February 2026, Agilent Technologies reported first-quarter 2026 sales of US$1,798 million, with net income of US$305 million, and raised full-year 2026 revenue guidance to a range of US$7.30 billion to US$7.50 billion while issuing new second-quarter revenue guidance of US$1,790 million to US$1,820 million.</li> <li>Management’s decision to increase full-year revenue guidance while first-quarter earnings per share were slightly lower than a year earlier highlights confidence in cost control and demand resilience across its end markets.</li> <li>With Agilent reaffirming and lifting parts of its 2026 outlook, we’ll now examine how this updated guidance shapes the company’s investment narrative.</li> </ul><p>This technology could replace computers: discover 22 stocks that are working to make quantum computing a reality.</p><h2>Agilent Technologies Investment Narrative Recap</h2><p>To own Agilent, you need to believe its tools and services remain essential to pharma, diagnostics and applied chemical labs, with recurring revenue and replacement cycles supporting steady demand. The latest guidance raise reinforces that view but does not materially change the key short term catalyst, which is execution on 2026 revenue and margin targets, or the biggest risk, which is ongoing tariff and supply chain pressure on costs.</p> <p>The most relevant recent update is Agilent’s decision in February 2026 to lift full year revenue guidance to US$7.30 billion to US$7.50 billion and issue second quarter revenue guidance of US$1,790 million to US$1,820 million. This higher top line outlook sits against the backdrop of tariff driven cost inflation and supply chain reorganization, so investors will likely focus on how effectively the Ignite operating model and related initiatives support margins as volumes grow.</p> <p>Yet while guidance has improved, the risk that tariff driven costs and supply chain complexity again pressure margins is something investors should be aware of...</p> <p>Read the full narrative on Agilent Technologies (it's free!)</p><p>Agilent Technologies' narrative projects $8.0 billion revenue and $1.7 billion earnings by 2028. This requires 5.8% yearly revenue growth and roughly a $0.5 billion earnings increase from $1.2 billion today.</p><p>Uncover how Agilent Technologies' forecasts yield a $169.67 fair value, a 47% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/69975872-a59c-46dc-9697-192d6a3dc958/chart/quote-price?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/69975872-a59c-46dc-9697-192d6a3dc958/chart/quote-price"/><figcaption>A 1-Year Stock Price Chart</figcaption></figure> <p>Four members of the Simply Wall St Community currently see Agilent’s fair value between US$125.16 and US$169.67, reflecting a wide band of individual expectations. Set against this, the raised 2026 revenue guidance highlights how differently people can weigh growth catalysts versus risks like tariff driven cost pressure, so it is worth comparing several views before forming your own.</p><p>Explore 4 other fair value estimates on Agilent Technologies - why the stock might be worth just $125.16!</p><h2>The Verdict Is Yours</h2><p>Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your Agilent Technologies research is our analysis highlighting 4 key rewards that could impact your investment decision.</li><li>Our free Agilent Technologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Agilent Technologies' overall financial health at a glance.</li></ul><h2>Ready For A Different Approach?</h2><p>Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:</p><ul><li>Outshine the giants: these 20 early-stage AI stocks could fund your retirement.</li><li>Uncover the next big thing with 32 elite penny stocks that balance risk and reward.</li><li>Find 49 companies with promising cash flow potential yet trading below their fair value.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

SBIO

<p>Agilent Technologies reported a 5.2% decline in stock price after raising its 2026 revenue guidance to $7.30-$7.50 billion, despite first-quarter earnings being slightly lower than the previous year. The company issued second-quarter revenue guidance of $1,790-$1,820 million, reflecting confidence in demand and cost control. However, ongoing tariff and supply chain pressures pose risks to margins. Analysts project a fair value range for the stock between $125.16 and $169.67, indicating differing views on growth versus risks. Investors are advised to consider these factors in their investment decisions.</p>

Simplywall

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

Agilent Tech

iShares Biotechnology ETF

SPDR S&P Health Equip

iShares US Medical Devices

Agilent Technologies (A) Is Down 5.2% After Raising 2026 Revenue Guidance – Has The Bull Case Changed?